Superdrol
Superdrol Dragon Pharma
Methyldrostanolone 10 mg/tab · 100 tabs · DHT-derived · non-aromatizing · oral
Class
DHT-Derived · 17α-Methyl
Oral AAS
Half-life
~8–10 hours
split dosing 2×/day
Aromatization
None
No estrogen conversion
User Level
Advanced
hepatotoxic — liver monitoring required
Typical Dose
10–20 mg
per day, split
Dosing Frequency
2× daily
with meals
Cycle Length
4–6 weeks
PCT 24 h after last tab
Lab Tested
$69.00
$69.00
In Stock
Shipping
Superdrol Dragon Pharma — Overview
Superdrol Dragon Pharma is an oral anabolic steroid containing methyldrostanolone (methasterone) at 10 mg per tablet, supplied in packs of 100 tabs. Methyldrostanolone is a 17α-methylated derivative of drostanolone (Masteron) with an additional 2α-methyl group that dramatically amplifies androgen receptor affinity and anabolic potency. The compound does not aromatize, produces no estrogenic water retention, and delivers rapid lean mass and strength gains within a short cycle window of 4–6 weeks.
Unlike the injectable form, oral methyldrostanolone undergoes first-pass hepatic metabolism before reaching systemic circulation — creating a higher peak liver concentration per dose and making diligent liver monitoring the central requirement of any Superdrol cycle. This page covers the pharmacology of oral methyldrostanolone, how it differs from the injectable formulation and other oral AAS, and the liver-protective protocol required to run it responsibly. Superdrol Dragon Pharma is available at Steroid Warehouse as part of the full Dragon Pharma oral lineup.
Methyldrostanolone Methasterone 10 mg/tab · 100 tabs DHT-Derived · 17α-Methyl Non-Aromatizing Lean Mass · Strength
On this page
About the Compound: Methyldrostanolone
Methyldrostanolone (2α,17α-dimethyl-5α-androstane-17β-ol-3-one) is structurally built on the drostanolone backbone with two key methylations. The 17α-methyl group enables oral bioavailability by resisting hepatic first-pass degradation — and is the source of hepatotoxicity. The 2α-methyl group dramatically increases androgen receptor binding affinity far beyond drostanolone, translating to anabolic potency that significantly exceeds testosterone on a per-milligram basis. Key pharmacological points:
- DHT-derived, fully 5α-reduced — methyldrostanolone does not aromatize and cannot convert to estrogen; no AI is required; gains are lean, dry, and dense with no estrogenic water retention
- First-pass hepatic metabolism — after oral ingestion, the compound passes through the liver before entering systemic circulation; peak hepatic concentration per dose is higher than with the injectable form; this is the primary reason liver enzymes should be monitored actively and why the cycle duration is capped at 4–6 weeks
- Short half-life (~8–10 hours) — requires splitting the daily dose into two equal administrations roughly 8–10 hours apart to maintain stable plasma levels throughout the day; taking both doses at once creates unnecessary peak hepatic exposure
- Strong SHBG displacement — methyldrostanolone competes aggressively with SHBG, increasing the free fraction of any co-administered testosterone or other androgens in the stack
- No progestogenic activity — no prolactin elevation, no progesterone-related side effects; this distinguishes it from nandrolone and trenbolone-based compounds
Active Compound
Methyldrostanolone (Methasterone)
Form
Oral tablet 10 mg/tab
Pack Size
100 tabs = 1000 mg total
Half-life
~8–10 hours
Aromatization
None
Progestogenic
None
Hepatotoxicity
Yes — first-pass + 17α-methyl
PCT start
24 hours after last tablet
Pack covers at 20 mg/day
1 pack for full 6-week cycle (840 mg used)
What Superdrol Does
- Rapid lean mass gains — methyldrostanolone drives muscle protein accretion through high-affinity androgen receptor activation; because there is no aromatization, every kilogram gained is lean tissue without glycogen- or water-driven weight that disappears post-cycle; users typically report 4–6 kg of lean mass over a 4–6 week cycle, with a high retention rate compared to wet-bulk compounds
- Strength gains disproportionate to mass gained — Superdrol is widely recognized for producing strength increases that outpace the modest scale of mass gained; this makes it particularly effective for strength sport athletes who need rapid performance gains without moving up a weight class
- Muscle hardness and vascularity — the DHT-derived dry profile combined with strong SHBG displacement produces a hard, dense, vascular appearance; there is no estrogenic bloat to mask muscularity, making Superdrol a functional choice for pre-competition finishing as well as lean bulk phases
- Amplification of co-administered androgens — by displacing testosterone and other AAS from SHBG, methyldrostanolone increases the bioavailable fraction of the entire hormonal environment; this synergistic effect means stacks with a testosterone base produce greater net anabolic output than the doses used would suggest in isolation
- HPG axis suppression — endogenous testosterone production is suppressed during the cycle via androgen-mediated negative feedback on LH and FSH; structured PCT is required after every cycle regardless of duration; the short half-life means HPG suppression can resolve relatively quickly once the compound clears
Who It's For
- What sets it apart: among oral AAS available through steroidwarehouse.com, Superdrol occupies a unique position as the only oral DHT-derived compound with potency in the same class as powerful wet orals like Dianabol — but without any estrogenic activity. Winstrol and Anavar are also dry DHT-derived orals, but their anabolic effect per milligram is significantly lower. Superdrol delivers Dianabol-level strength and mass gains in a completely dry, aromatization-free package, at the cost of greater hepatotoxicity than any of the milder oral alternatives.
- Best scenario: advanced users running a short 4–6 week lean bulk or strength peak who need maximum dry anabolic output from an oral compound; athletes in strength sports where every kilogram of lean mass matters and water retention is a liability; experienced users who prefer oral-only convenience without the injection management of the injectable form; users using it as a 4-week oral kickstart to a longer testosterone base cycle, where its rapid onset builds mass and strength while the injectable ester reaches steady state.
- Choose something else instead: users running their first AAS cycle should not start with a 17α-methylated compound; anyone with elevated baseline ALT/AST or a history of liver issues should avoid Superdrol entirely; users wanting to run an oral compound for more than 6 weeks should choose Anavar 10 or Winstrol 50 with their lower hepatotoxic profile; female athletes should avoid methyldrostanolone due to strong virilization potential.
Superdrol vs Alternatives
| Compound | Key Difference | Choose Superdrol (oral) When | Choose Alternative When |
|---|---|---|---|
| Superdrol Inj Dragon Pharma | Same active compound (methyldrostanolone) in injectable oil form; injectable bypasses first-pass metabolism, potentially reducing peak hepatic concentration per dose; daily or EOD injections vs twice-daily tablets; otherwise pharmacologically identical | You prefer oral convenience and do not want to manage daily injections; GI tolerance of the oral is not an issue | You prefer injectable administration, want to avoid first-pass hepatic exposure, or require more precise plasma level control via daily injection |
| Dianabol 20 Dragon Pharma | Methandrostenolone; 17α-methylated oral but aromatizes moderately; produces wet, full gains with glycogen loading and water retention; similar hepatotoxicity profile; AI management required; different aesthetic outcome | Lean, dry gains are the priority and you want no estrogenic sides, no AI, and no post-cycle water loss | You are in a mass-building phase where the full, saturated appearance of estrogenic gains is acceptable and you want maximum scale weight increase; Dianabol 20 typically produces larger absolute weight gains |
| Winstrol 50 Dragon Pharma | Stanozolol; DHT-derived oral; non-aromatizing; significantly lower hepatotoxicity than methyldrostanolone; can be run 8–10 weeks; lower anabolic potency per milligram; better joint and lipid profile at equivalent doses | Maximum oral anabolic potency in a short window is the goal and you accept the strict liver monitoring requirement | You want a dry oral compound for a longer cycle (8–10 weeks) with lower liver stress and moderate hardening effects; Winstrol 50 is the safer long-cycle dry oral |
| Anavar 10 Dragon Pharma | Oxandrolone; DHT-derived oral; lowest hepatotoxicity among oral AAS; mild androgen receptor activity; suitable for longer cycles (8–10 weeks) and for strength-focused protocols with minimal mass gain; well-tolerated by most users | You need maximum dry anabolic output in 4–6 weeks and are prepared to manage the liver monitoring protocol | You want a safer oral for longer cycles, are a first-time oral user, or prioritize strength and body composition over rapid mass accumulation; Anavar 10 carries significantly lower hepatic risk |
Combinations
| Goal | Stack | Notes |
|---|---|---|
| Oral kickstart to a long injectable cycle | Superdrol 10–20 mg/day weeks 1–4 + Enantat 250 300–500 mg/week (12–16 weeks) | The most common use case for oral Superdrol; Enantat 250 takes 3–4 weeks to reach steady state — Superdrol fills that window with rapid strength and mass gains; discontinue Superdrol after week 4 and continue on Enantat 250 alone; liver support throughout the Superdrol phase; no AI needed for Superdrol, but have one on hand for the testosterone phase |
| Lean bulk with minimal water | Superdrol 10–20 mg/day + Primobolan 100 400–600 mg/week | Both compounds are dry and non-aromatizing; Primobolan 100 is non-methylated and mild on the liver, making it the ideal injectable base to pair with an oral methylated compound; keep Superdrol to 4 weeks within the longer Primobolan cycle; ALT/AST check at week 2 and week 4 of the Superdrol phase |
| Short-cycle lean bulk (all short-acting) | Superdrol 10–20 mg/day + Propionat 100 300–400 mg/week | Both compounds clear within days of stopping; PCT can begin 3–5 days after the last Propionat 100 injection; useful for users with defined time windows (competition prep, travel); 4–6 week total cycle; full liver support protocol required throughout |
| Hardness and density (pre-contest / recomp) | Superdrol 10 mg/day + Masteron 100 300–400 mg/week + testosterone base | Two DHT-derived dry compounds at moderate doses; Superdrol provides the potent anabolic drive while Masteron 100 contributes hardness and SHBG binding; keep Superdrol at 10 mg/day when stacking to limit cumulative androgenic and hepatic load; testosterone base is mandatory to prevent low-E2 joint and libido issues |
| Strength peak (4-week focused protocol) | Superdrol 20 mg/day + testosterone base at maintenance dose | Short, focused 4-week protocol targeting strength competition or performance testing; Superdrol provides the rapid neuromuscular strength output; testosterone base prevents HPG-related fatigue and libido suppression; mandatory ALT/AST check at week 2; PCT starts 24 hours after last Superdrol tablet if test base has also been stopped |
Side Effects & Management
| What May Occur | Background | How to Handle It |
|---|---|---|
| Hepatotoxicity (elevated ALT / AST) | Oral methyldrostanolone undergoes first-pass hepatic metabolism, creating higher peak liver concentrations than the injectable form; the 17α-methyl group is processed hepatically and is the direct mechanism of enzyme elevation; ALT/AST rise is expected on any methylated oral cycle and is the primary factor limiting cycle duration to 4–6 weeks | Begin liver support on day 1: Liv.52 2 tabs twice daily + Mucinac (NAC) 600 mg twice daily + Ursocol (UDCA) 300 mg twice daily; check ALT/AST at week 2 and week 4; pause immediately if ALT exceeds 3× upper limit of normal; eliminate alcohol completely during the cycle; do not stack with other 17α-methylated compounds |
| Back pumps / muscle pumps | One of the most consistent and Superdrol-specific side effects; presents as painful cramping in the lower back erectors and other large muscle groups during training; reported by a high proportion of users at effective doses; likely linked to SHBG displacement and rapid intracellular fluid shifts in muscle tissue; not dangerous but can significantly impair training sessions | High-volume hydration (3–4 L water/day); taurine supplementation 3–5 g/day is widely reported to reduce severity; reduce training volume on compound movements; lower rest intervals can worsen pumps — extend rest periods during the Superdrol phase; if severe, dose reduction to 10 mg/day is preferable to stopping the cycle abruptly |
| Lethargy / fatigue | Persistent low energy, mental fatigue, and reduced motivation; typically appears at 2–3 weeks into the cycle; mechanism not fully characterized; can impair quality of life and training performance despite positive physical progress; widely reported across users and dose ranges | Keep cycles to 4–6 weeks maximum; ensure adequate caloric surplus — lethargy is significantly worse in a deficit; prioritize sleep quality; symptoms resolve promptly after cycle end; if fatigue is severe at 20 mg/day, reduce to 10 mg/day before discontinuing |
| Cardiovascular — HDL suppression | 17α-methylated androgens strongly suppress HDL via hepatic lipase upregulation; methyldrostanolone lacks estrogenic activity, removing one natural HDL-protective mechanism; oral first-pass through the liver amplifies this effect compared to injectable administration; significant HDL reduction during a Superdrol cycle is expected | Lipid panel at baseline and end of cycle; Rosulip (Rosuvastatin) if LDL is elevated; omega-3 supplementation; keep dietary saturated fat low during the cycle; cardio 2–3×/week; HDL typically recovers 4–6 weeks post-cycle |
| Blood pressure elevation | SHBG displacement increases free androgen load; combined with the cardiovascular strain of intense training and reduced vasodilatory estrogen, BP elevation is common particularly at doses above 20 mg/day or when stacked with high-dose testosterone | Weekly BP monitoring; target <130/85 mmHg; Sartel (Telmisartan) or Amlip (Amlodipine) for persistent readings above 140/90; moderate cardio throughout the cycle |
| Androgenic — acne, hair loss | DHT-derived compound that is already 5α-reduced; 5α-reductase inhibitors (finasteride, dutasteride) have no effect on its androgenicity; acne and androgenic alopecia are determined by individual genetic sensitivity; notable androgenic activity despite the relatively low androgenic rating on paper | Topical acne protocols; Accutane Dragon Pharma for severe or cystic acne; Minoxidil Dragon Pharma for hair retention in susceptible users; finasteride is not applicable for this compound |
| Low-estrogen symptoms (without testosterone base) | Methyldrostanolone produces no estrogen; running it without an adequate testosterone base creates a low-E2 environment that manifests as reduced libido, potential ED, and joint dryness; this is not a direct side effect of the compound but a consequence of HPG suppression combined with zero aromatization | Always pair with an appropriate testosterone base at a dose sufficient to maintain E2 in range; the injectable testosterone range at steroidwarehouse.com (Enantat 250, Propionat 100) covers all cycle lengths; do not run methyldrostanolone as a standalone compound without exogenous testosterone unless the cycle is extremely short and the user accepts the libido risk |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| ALT / AST (liver enzymes) | Baseline (mandatory); week 2; week 4; end of cycle | Baseline ALT target <40 U/L; on-cycle elevation of 1.5–2× ULN is common; pause use if ALT exceeds 3× ULN (>120 U/L); the oral first-pass route makes this the single most critical monitoring parameter — do not skip the week 2 check |
| Lipid panel (HDL, LDL) | Baseline; end of cycle | HDL target >40 mg/dL; oral methylated AAS reliably suppress HDL and the oral route amplifies this effect; document baseline to quantify actual suppression; LDL target <130 mg/dL; typically recovers 4–6 weeks post-cycle |
| Blood pressure | Baseline; weekly throughout cycle | Target <130/85 mmHg; weekly self-monitoring is adequate; readings consistently above 140/90 warrant antihypertensive intervention before continuing the cycle |
| LH / FSH | Baseline; PCT week 4 | Expected suppression to near-zero on cycle; recovery to >2 IU/L by PCT week 4 confirms HPG axis restart; the short half-life and typical 4–6 week cycle duration generally support faster recovery than long-ester injectable cycles |
| Hematocrit / CBC | Baseline; end of cycle | Target hematocrit <52%; documents pre-cycle status; androgen-stimulated erythropoiesis is less pronounced on short oral cycles than long injectable protocols but worth tracking as a baseline |
| Total testosterone | Baseline (mandatory pre-cycle) | Documents natural testosterone level before suppression begins; post-PCT target is recovery to within 10–15% of pre-cycle baseline within 8–10 weeks of completing SERMs |
PCT
Oral methyldrostanolone has a half-life of approximately 8–10 hours and no ester; the compound is fully cleared within 24–48 hours of the last dose. PCT can begin as soon as 24 hours after the last tablet — making timing simpler than long-ester injectable cycles. HPG suppression from a 4–6 week cycle is typically less entrenched than from a 12–16 week injectable cycle, supporting a standard SERM protocol without mandatory HCG pre-loading in most cases.
| Phase | Protocol | Notes |
|---|---|---|
| PCT start | Begin 24 hours after the last Superdrol tablet | The compound clears rapidly; no washout period is needed; if stacked with a long-ester testosterone (Enantat 250), PCT timing follows the ester — typically begin SERMs 21 days after the last testosterone injection, not 24 hours after the last Superdrol tab |
| PCT weeks 1–4 | Nolvadex Dragon Pharma 40 mg/day weeks 1–2 → 20 mg/day weeks 3–4; or Clomid Dragon Pharma 50 mg/day weeks 1–2 → 25 mg/day weeks 3–4 | Single SERM protocol is adequate for a 4–6 week methyldrostanolone cycle; Nolvadex is the preferred choice for its more favorable side effect profile; add Clomid to the protocol if LH/FSH recovery is slow at the PCT week 2 check; dual SERM only if prior cycles have demonstrated consistently sluggish HPG recovery |
| HCG (optional) | HCG 5000 IU Dragon Pharma 500 IU EOD for 10 days before starting SERMs, if the Superdrol cycle included a long-ester testosterone for ≥12 weeks | Not mandatory for a standalone 4–6 week oral Superdrol cycle; consider adding HCG pre-loading only when the full stack duration was longer than 8 weeks, or if prior cycles have resulted in poor testicular recovery |
| Post-PCT bloodwork | Total testosterone, LH, FSH — 4–6 weeks after stopping SERMs; also recheck ALT/AST | Testosterone should return to within 10–15% of pre-cycle baseline; LH and FSH >2 IU/L confirms axis recovery; ALT/AST should normalise within 4–6 weeks post-cycle — confirm this is the case before planning any subsequent cycle |
Practical Summary
- Start liver support on day 1 — not when symptoms appear; Liv.52 + NAC (Mucinac) + UDCA (Ursocol) as a triple stack; ALT/AST at week 2 is the single most important check on any oral methylated cycle; stop immediately if ALT exceeds 3× ULN
- Split the daily dose into two equal parts taken ~8–10 hours apart with meals; taking the full day's dose at once increases peak hepatic load without improving anabolic effect
- Always run a testosterone base alongside Superdrol; the zero-estrogen environment from a methyldrostanolone-only cycle suppresses libido, dries joints, and impairs recovery; Enantat 250 or Propionat 100 are the standard base options
- Back pumps and lethargy are nearly universal at effective doses; taurine 3–5 g/day addresses pumps; lethargy resolves within days of stopping the compound; do not extend the cycle trying to push past the fatigue
- 1 pack (100 tabs × 10 mg) covers a complete 6-week cycle at 20 mg/day with 160 mg to spare; no partial packs needed for standard cycles
- PCT begins 24 hours after the last tab (oral-only cycle); ALT/AST and total testosterone should be rechecked 4–6 weeks after completing SERMs before planning the next cycle
Superdrol Dragon Pharma delivers methyldrostanolone in a convenient oral format that requires no injection management while providing the same potent anabolic and strength-building output the compound is known for. It remains one of the most effective oral options at steroidwarehouse.com for users targeting lean, dry mass gains in a short, focused cycle — particularly as a kickstart to a longer injectable base or as a standalone 4-week strength protocol. The mandatory trade-off is a strict liver monitoring requirement and a hard cap on cycle duration; athletes who work within those limits consistently report high-quality gains with minimal post-cycle losses.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks, showing increased fat-free mass, muscle size, and strength, especially when combined with resistance training; foundational evidence for supraphysiologic androgen anabolic effects | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — synthetic testosterone-derived AAS pharmacology, androgen receptor mechanism, anabolic-androgenic effects, oral and injectable steroid classes, misuse patterns, monitoring, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — testosterone and androgen derivative mechanisms of action, androgen receptor activity, HPG axis suppression, 5α-reduction, estradiol aromatization, synthetic androgen pharmacology, and androgen misuse context | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| Seminars in Liver Disease / PubMed | Ishak & Zimmerman 1987 — hepatotoxic effects of anabolic-androgenic steroids; covers liver injury patterns linked to 17α-alkylated androgens, including cholestasis, peliosis hepatis, hepatic adenoma, and other steroid-related liver complications | Ishak KG & Zimmerman HJ (1987) ↗ |
| Journal of Clinical Gastroenterology / PubMed | Singh et al. 2009 — methasterone-specific case report describing severe hepatotoxicity caused by a methasterone-containing performance-enhancing supplement; directly relevant to methyldrostanolone/Superdrol liver-risk discussion | Singh V, et al. (2009) ↗ |
What is Superdrol?
Superdrol is an oral anabolic steroid (Methyldrostanolone) for muscle growth; see What is Superdrol. It's highly potent—consult professionals for safe use.
Is there anything stronger than Superdrol?
Few compounds like Methyl-1-Test or Oral Tren may be stronger but carry higher risks; see Is There Anything Stronger Than Superdrol. Consult professionals for alternatives.
How does Superdrol work?
It binds androgen receptors to promote muscle growth and strength; see Mechanism of Action. It delivers rapid gains—monitor with labs.
Is Superdrol safe?
It's safe with strict dosing and monitoring; see Side Effects. Manage risks with liver support and PCT—consult professionals for safety.
What is Superdrol used for?
It's used for rapid muscle growth and strength in bulking; see Key Benefits. It suits advanced users—use with professional oversight.
How long does it take to notice effects from Superdrol?
Due to its fast-acting oral nature, many users report noticeable improvements in strength, muscle fullness, and workout performance within the first few weeks.
What are the possible side effects of Superdrol?
Potential side effects may include elevated blood pressure, acne, oily skin, liver stress, changes in cholesterol levels, and suppression of natural testosterone production.
What makes Superdrol different from other oral steroids?
Superdrol is known for its exceptional strength-to-weight gain ratio, helping users achieve significant increases in strength and muscle density without the excessive water retention often associated with some other oral compounds.
Related Products
Available Domestic
Lab Tested
Masteron 100 Dragon Pharma
Drostanolone Propionate 100 mg/ml · DHT-derived injectable · non-aromatizing
Class
DHT-Derived
Injectable AAS
Ester / Active Life
Propionate
~2–3 days
Aromatization
None
No estrogen conversion
User Level
Intermediate
to Advanced
Typical Dose
300–500 mg
per week
Injection Frequency
EOD
every other day
Cycle Length
8–12 weeks
typical range
Available Domestic
Lab Tested
Anadrol Inj Dragon Pharma
Oxymetholone 50 mg/ml · DHT-derived injectable · non-aromatizing via aromatase
Class
DHT-Derived
Injectable AAS
Ester / Active Life
No ester
~8–16 hours
Aromatization
None
No estrogen via aromatase
User Level
Intermediate
to Advanced
Typical Dose
50–100 mg
per day
Injection Frequency
Daily
short active life
Cycle Length
4–6 weeks
typical range
Lab Tested
Cagrilintide Dragon Pharma
Long-acting amylin analogue · calcitonin receptor agonist · 10 mg vial
Category
Amylin Analogue
Weight management peptide
Form / Strength
Lyophilized vial
10 mg · reconstitute before use
Context
Appetite suppression
weight loss · metabolic support
Administration
SC injection
once weekly
Starting Dose
0.3 mg
per week
Target Dose
2.4–4.5 mg
16-week titration
Duration
Long-term
maintenance after titration
Available Domestic
Best Seller
Lab Tested
Cialis DP Dragon Pharma
Tadalafil 20 mg · PDE5 inhibitor · up to 36-hour duration
Category
PDE5 Inhibitor
Erectile dysfunction
Form / Strength
Oral tablet
20 mg per tab
Context
ED / sexual function
on-demand or daily protocol
Monitoring
Blood pressure
if on antihypertensives
Typical Dose
10–20 mg
on-demand · or 5 mg/day
Onset
30–45 min
unaffected by food
Duration
Up to 36 h
per dose
Available Domestic
Lab Tested
Clenbuterol Dragon Pharma
Beta-2 adrenergic agonist · thermogenic · 40 mcg per tablet
Category
Beta-2 Agonist
Thermogenic / fat loss
Form / Strength
Oral tablet
40 mcg per tab
Context
Fat loss · cutting
metabolic rate increase
Monitoring
Heart rate
blood pressure · tremors
Starting Dose
40 mcg/day
increase by 20 mcg every 2–3 days
Peak Dose
80–160 mcg
men · women: 40–100 mcg
Protocol
2 wk on
2 wk off · or with ketotifen
Available Domestic
Lab Tested
Cut Mix 150 Dragon Pharma
Test P 50 · Tren A 50 · Masteron P 50 · 150 mg/ml
Category
Injectable AAS Blend
3-compound / short esters
Composition
150 mg/ml total
Test P · Tren A · Drost P
Context
Cutting · Recomp
lean mass · fat loss · density
Administration
IM injection
every other day (EOD)
Typical Dose
1–1.5 ml EOD
~525–787 mg/week
Frequency
EOD
short ester schedule
Cycle Length
8–10 weeks
PCT 3–4 days after last inj
Lab Tested
CY3 Dragon Pharma
Clenbuterol · Yohimbine HCl · Liothyronine T3 · 37 mcg/tab
Class
Thermogenic Stack
3-compound oral tablet
Mechanism
Beta-2 · Alpha-2 · T3
triple fat-loss pathway
Context
Cutting
fat loss · metabolic rate
Administration
Oral tablet
split daily doses, morning
Typical Dose
1–2 tabs/day
37–74 mcg/day
Frequency
Daily (AM)
avoid afternoon / evening
Cycle Length
4–8 weeks
2-week break recommended
Lab Tested
Deca 200 / NPP 150 Dragon Pharma
Nandrolone Decanoate 200 mg + Phenylpropionate 150 mg · 350 mg/ml
Class
Anabolic Steroid
dual nandrolone ester blend
Half-life
Deca ~15d · NPP ~5d
dual-phase release
Context
Bulking · Joints
mass, recovery, collagen
Administration
IM injection
weekly or E5D
Typical Dose
300–500 mg/wk
always with testosterone base
Frequency
Weekly / E5D
stable dual-ester levels
Cycle Length
12–16 weeks
PCT 3 weeks after last pin